All In Biotech

Drug Trial Radar · NCT07070518

Study of GV20-0251 in Participants With Solid Tumor Malignancies

An Open-Label Phase 1/2A Study of GV20-0251 in Participants With Advanced and/or Refractory Solid Tumor Malignancies

Last checked: Nov 20, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Jul 11, 2025

Primary completion

Jul 16, 2027

Study completion Sep 16, 2028

Sponsor

Lead sponsor
GV20 TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Conditions

  • Solid Tumor Cancer
  • Adult Refractory Cancer
  • Endometrial Carcinoma (EC)
  • Squamous Head and Neck Carcinoma
  • pMMR/MSS Adenocarcinoma of the Colon or Rectum
  • Non-Small Cell Lung Cancer
  • Melanoma
  • HCC - Hepatocellular Carcinoma
  • Small Cell Lung Cancer

Interventions

  • GV20-0251Drug

    Part A: Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks Part B: GV20-0251 preliminary RP2D administered by IV infusion once every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate anti-tumor activities with GV20-0251Time frame: From Cycle 1 Day 1 dosing (each cycle is 21 days) until disease progression or end of study (whichever occurs first, up to 24 months)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.